Assess your compounds for developmental toxicity without undertaking resource-intensive and costly rodent or rabbit studies and with more relevant human cellular models.
- Get data in only a few weeks at a fraction of the cost of animal testing with our key platform in support of US EPA’s ToxCast and Virtual Tissue Model programs.
- Utilize either human embryonic stem cells (hESCs) or human induced pluripotent stem cells (iPSCs) to predict developmental toxicity based on changes in cellular metabolism following chemical exposure.
- Customize to meet your needs for specific compound types, such as gaseous compounds, or to assess different concentrations at which the test article has the potential to elicit developmental toxicity.
Assess your compounds for cardiovascular toxicity, a major cause leading to compound attrition throughout drug discovery and development or withdrawal of FDA-approved drugs from the market.
- Get an early indication of a drug candidate’s cardiotoxicity potential and identify functional or structural cardiotoxicants with a single assay.
- Assess the cardiotoxicity potential based on changes in human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) metabolism and viability.
- Combine with other assays or endpoints for a comprehensive understanding of a compound’s cardiotoxicity liability.
TESTED & PROVEN
devTox quickPredict Developmental Toxcicity Assay.
Powerful human in vitro systems for toxicology and compound safety screening.
Contact Us for a Quote
To discuss your project, fill out this form and we’ll get back to you shortly.
Stemina’s neurological disorders business unit has developed a test to aid in the earlier diagnosis of autism spectrum disorder.